TPD52 and prostate carcinoma: Work by our laboratory and that of others revealed that both PC-1/PrLZ and 4E-BP1 were overexpressed in prostate cancers [14, 40], therefore, the PC-1/PrLZ-4E-BP1 signaling pathway represents a logical therapeutic target to increase tumor cell radio- and chemo-sensitivity.